Biomarkers for Immunotherapy
Originally presented at HOPA's 14th Annual Conference, March 2018.
Since the advent of novel immunotherapy agents, ushered in by ipilimumab, patient selection using assays to predict response has evolved. Some, but not all, checkpoint inhibitors are accompanied by a requirement to test tumor biopsy material for expression of a relevant marker (programmed death-ligand 1 [PD-L1]) prior to initiation; however, even agents in the same class have differing requirements based on tumor type. Additional biomarkers beyond PD-L1, including genomic measures and other immune-based targets, may also help to stratify populations for improved response. However, some have argued that testing is globally unnecessary because of responses in patients shown to be negative for the biomarker of interest. This session will explore how different biomarkers that predict activity in a given patient or population are used, including their benefits and limitations. Characteristics of assay performance will be discussed, as well as how laboratory, tissue collection, and clinical and treatment variables may influence results. Finally, discussion of debates about the clinical use of microsatellite instability in broad populations and PD-L1 interpretation across non-small-cell lung cancer patients will highlight clinical challenges in checkpoint inhibitor use.
R. Donald Harvey, PharmD BCOP FCCP FHOPA; Jacob K. Kettle, PharmD BCOP; Josiah Land, PharmD BCOP
Patient Management & Therapeutics
The Hematology/Oncology Pharmacy Association (HOPA) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. An ACPE statement of credit will be issued only upon completion of the pre/post- assessment and a post-activity evaluation form. ACPE credit must be claimed by March 22, 2021.
This activity has been approved for .125 CEU
This course is also included as part of the Best of 2018 Annual Conference Recordings Bundle.
Release Date: September 26, 2018
Expiration Date: March 22, 2021